Next 10 |
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while ...
TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline data from the 48-week interim analysis of 104 enrolled patients is anti...
2024-05-19 01:10:48 ET Summary Anti-inflammatory drugs are likely to have limited effects on Alzheimer's disease because they are not stopping early oxidation and nitration. Neuroinflammation in Alzheimer's disease is primarily caused by oxidative and nitrosative stress. Inhib...
Ongoing progress toward last patient enrolled in pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1), expected Q2 2024 Topline data from 48-week interim analysis expected H1 2025...
2024-03-19 06:53:57 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Cyclo Therapeutics (NASDAQ: CYTH ) just reported results for the fourth quarter of 2023. Cyclo Therapeutics reported earnings per share of -23 cents. The company repor...
2024-03-18 10:59:35 ET More on Cyclo Therapeutics Seeking Alpha’s Quant Rating on Cyclo Therapeutics Historical earnings data for Cyclo Therapeutics Financial information for Cyclo Therapeutics Read the full article on Seeking Alpha For further...
Continued progress of pivotal Phase 3 study (TransportNPC™) evaluating Trappsol ® Cyclo™ for the treatment of Niemann-Pick Disease Type C1 (NPC1) toward 48-week comparative interim analysis data readout, planned for Q1 2025 Aligned development strategy for Trappsol ...
Lendway Inc. (LDWY) is expected to report for quarter end 2023-12-31 Hongchang International Co Ltd Com (New) (HCIL) is expected to report for Q4 2023 BioStem Technologies Inc (BSEM) is expected to report $0.47 for Q4 2023 Nicox SA (NICXF) is expected to report $-0.07 for Q4 2023 ...
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the ...
News, Short Squeeze, Breakout and More Instantly...
Cyclo Therapeutics Inc. Company Name:
CYTH Stock Symbol:
NASDAQ Market:
Cyclo Therapeutics Inc. Website:
Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that...
NEWARK, N.J., June 14, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), today reported its financial results for the third quarter and the first nine months of fiscal 2024 ended April 30, 2024. “During fiscal 2024, we have continued to develop our existing portfolio while ...
TransportNPC™ is the most comprehensive ongoing controlled pivotal study regarding patient size, global footprint, duration and clinical outcomes for the treatment of Niemann-Pick Disease Type C1 (NPC1) Topline data from the 48-week interim analysis of 104 enrolled patients is anti...